GLMD Eocene Ltd.
3.400USD-2.30%Mkt Cap: 4.95M $P/E: —20d ago
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic …
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.27BUSDP/E 30.7
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) Galmed announced the development of a lipid nanoparticle formulation of Aramchol designed to target heart tissue, marking a potential expansion of the drug beyond its existing liver and gastrointestinal development programs. Key Investor TakeawaysGalmed (NASDAQ:GLMD) developed a novel cardiac-targeted formulation of Aramchol using lipid nanoparticles in collaboration with Barcode Nanotech. | ||